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ABSTRACT
A role for Fgl2 (fibroleukin) in thrombophilic-associated human fetal loss has been
indicated by previous studies. Clotting of vascular vessels of the placenta and fetus interferes
with adequate blood circulation.
The human Fgl2 gene was sequenced with identification of six SNPs, suggesting an
association with a population of women suffering from recurrent fetal losses. A small sample
size however, prevented precise statistical analyses of this association. In vitro, human
endothelial cells (HUVECs) were not found to constitutively express Fgl2, but were shown to
up-regulate its expression when challenged with IFN-γ and TNF-α. Interestingly, TNF-α was
only shown to induce expression of Fgl2 in HUVECs from male donors and not female donors.
A larger case-control study is needed to examine the relationship of Fgl2 with recurrent fetal loss.
The role of estrogen in the Th1-induced expression of Fgl2 by HUVECs should also be
examined.
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INTRODUCTION
Thrombophila is a condition when a patient has a tendency to form blood clots.
This can be a life-threatening event if the clots restrict blood flow. Recent research
suggests a possible correlation between inherited thrombophila and recurrent fetal loss.
Genetic markers for these clotting factors include factor V Leiden, the prothrombin
G20210A polymorphism, activated protein C resistance, and protein S deficiency in first
trimester losses. Factor V Leiden has been shown to be significantly associated with
early (before 13 weeks gestation) as well as late (after 22 weeks gestation) pregnancy
losses. Fibrinogen-like protein 2 (Fgl2) may be another genetic marker for thrombosis
related to recurrent fetal loss.
Fibrinogen-like protein 2 (Fgl2, fibroleukin) was first isolated in 1987 by Koyama,
et al.1 from cytotoxic T lymphocytes. Fgl2 was described as a novel prothrombinase and
procoagulant due to its ability to bypass the traditional coagulation pathway.
The coagulation system consists of an extrinsic and intrinsic pathway. The
extrinsic pathway is the initiation of a cascade of sequential activation of coagulation
factors. The intrinsic pathway employs the use of cofactors that are involved in the
maintenance of this clotting cascade. At the heart of this cascade, tissue factor (a
procoagulant) initiates the activation of several factors culminating in the activation of
prothrombin to thrombin (by factor Xa in the presence of coenzyme Va). Thrombin then
cleaves the zymogen fibrinogen to fibrin, which is subsequently cross-linked and
becomes the fibrin clot. Fibroleukin was shown to directly cleave prothrombin to
thrombin in a murine model for virus-induced fulminant hepatic failure2,3,and 4.
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Studies conducted in mouse model systems demonstrate the role of Fgl2 in
thrombosis during MHV-3-virus-induced hepatitis5. mRNA transcripts of Fgl2 and Fgl2
protein were detected in liver reticuloendothelial cells, followed by fibrin deposition and
widespread hepatic necrosis following MHV-3 infection. Neutralizing antibodies to Fgl2
were able to prevent this scenario, implicating the role of Fgl2 in the fibrin deposition and
consequent hepatic pathology. Now linked to thrombosis, Fgl2 was evaluated for a
possible role in fetal loss.
Interference of blood supply to the fetus through clotting of the placental/fetal
vessels is caused by proteins or cytokines that are produced by immune cells within the
lining of the uterus. Initial exposure to pro-inflammatory cytokines is necessary to
stimulate invasion of the blastocyst and formation of new blood vessels at the time of
implantation. Prolonged exposure of pro-inflammatory cytokines to the pregnancy is
detrimental. For pregnancy to be successful, a change in balance of secretion of
cytokines from pro-inflammatory to anti-inflammatory cytokines must occur (shift from a
Th1 to a Th2 response). During idiopathic recurrent miscarriage, studies point to a Th1
response dominating over a Th2 response. This failure to shift from a Th1 to a Th2
response in early pregnancy (pro-inflammatory to anti-inflammatory cytokines) is known
to be detrimental to pregnancy.
Loss of pregnancies in mice after IFN-γ injections has been demonstrated6. The
same study also showed the ability of IFN-γ to up-regulate the expression of Fgl2 in the
basal uterine deciduas of mice and went on to show that the inhibition of Fgl2
prothrombinase activity was able to prevent cytokine-induced fetal loss normally
characterized by fibrin deposition.
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Other studies provide additional support to the hypothesis that Th1 cytokines upregulate the expression of Fgl2. One study demonstrates the ability of IL-2 to upregulate Fgl2 expression in a murine macrophage cell line, whereas IL-4 (a Th2 cytokine)
did not increase Fgl2 production by the mouse macrophages7. TNF-α treatment of
cultured porcine endothelial cells was also shown to increase the expression of porcine
Fgl28. These studies provide evidence that Fgl2 expression is up-regulated by cytokines
released during a Th1-type response.
Promoter, intron, and exon regions within the human Fgl2 gene have been
identified, along with different polyadenylation addition signals, which give rise to two
mRNA species7. Despite the work completed on mouse Fgl2, little has been published
regarding the regulation of the human gene and its characterization for polymorphisms.
Constitutive expression of human Fgl2 has been shown in CD4+, CD8+, and cells
of the small intestine9,10. Conditional expression has been demonstrated by the increased
presence of Fgl2 mRNA seen in endothelial cells and macrophages in patients with acute
and viral hepatitis5. Uterine tissues taken from fetal losses during the first trimester also
show an increased expression of Fgl2 in trophoblast cells6.
Estrogen has long been known to have a protective role in thrombophilia
environments. The risk of cardiovascular disease in pre-menopausal women is much
lower than that of men. The incidence of coronary artery disease and stroke in postmenopausal women (when estrogen levels decrease) rises to equal that of men. Estrogen
has also been known to play an important role in the maintenance of a healthy pregnancy.
Throughout pregnancy, a steady increase in the amount of estrogen produced by the
placenta regulates the production of progesterone over the full term. Estrogen also guides
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the maturation of fetal lungs, kidneys, liver, and adrenal glands and plays a role in
promoting blood flow within the uterus. The association between estrogen and
thrombosis may also indicate a relationship with estrogen and the thrombosis associated
with Fgl2 expression.
In this study, the human Fgl2 gene was sequenced and variations from the
published sequence were identified. The frequencies of these polymorphisms were
established in a control population as well as a population of women suffering from
recurrent fetal losses. Twelve single-nucleotide polymorphisms (SNPs) were identified
in the gene and analyzed for an association with recurrent fetal loss. The expression of
Fgl2 by human umbilical vein endothelial cells (HUVECS) was examined under normal
and Th1 cytokine conditions to evaluate if Th1 cytokines influence the expression of the
Fgl2 gene in human endothelial cells. Cells were also challenged with estrogen in
combination with Th1 cytokines and evaluated for Fgl2 expression.
MATERIALS AND METHODS
PCR/Sequencing
A population of human DNA samples was collected consisting of cases and
controls. All samples were from female donors and cases were defined as females who
had suffered from three or more consecutive miscarriages. PCR primers were designed
to amplify the Fgl2 gene (NCBI accession number AF468959)11 in 10 short fragments
defining nucleotide +1 as the start of translation. Table 1 shows the PCR primers used as
well as their nucleotide location in the gene. A PCR master mix was prepared consisting
of forward and reverse primers, Amplitaq DNA polymerase (Applied Biosystems),
deionized H2O, and the PCR master mix MasterAmp 2x PCR PreMix J (Epicentre).
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Table 2A gives the final concentrations of all ingredients used in the PCR mix.
MasterAmp J includes 200μM of each dNTP, buffer, 3.0mM MgCl2, and 8x MasterAmp
PCR Enhancer (with Betaine). After adding 8ng/μl DNA template to the reaction
mixture, the experiment was run under the thermocycling conditions listed in Table 2B.
As shown in Table 2B, the DNA was denatured at 950C for one minute, annealed at 550C
for one minute, and extended at 720C for one minute.
An ExoSAP-IT (USB Corporation) clean-up reaction was performed on the PCR
product to prepare the samples for a sequencing PCR. Six microliters of ExoSAP-IT was
added to 10μl PCR product and was held at 370C for 30 minutes and then heated to 990C
for 15 minutes as shown in Table 3. The BigDye® Terminator v1.1 Cycle Sequencing
Kit (Applied Biosystems) was used to prepare the samples for automated sequencing on
the ABI 3100 genetic analyzer. A sequencing master mix was made consisting of
Sequencing Mix v.1.1, Sequencing Buffer, 3.2pm/μl sequencing primer, deionized water,
and 3μl PCR product. Final concentrations of each additive are listed in Table 4. An
additional ethanol precipitation reaction (Table 5) was added to further clean-up the
samples before the addition of the 20μl formamide to each sample. Samples were then
sequenced on the ABI3100 in a 96-well format.
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Cell Culture
Three HUVEC cell lines (from two newborn female Caucasian and one newborn
male Caucasian) were obtained from Clonetics-Bio Whittaker and subcultured in an
EGM-MV (Cambrex) medium containing 10ng/ml human recombinant epidermal growth
factor (hEGF), 1 μg/ml hydrocortisone, 50 μg/ml gentamicin, 50 ng/ml amphotericin-B, 3
mg/ml bovine brain extract (BBE) and 5% FBS (fetal bovine serum). At 80-90%
confluence, the cells (P5) were challenged with 10ng/ml of recombinant human IL-2,
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10ng/ml recombinant human TNF-α/TNFSF1A, or 10ng/ml recombinant human IFN-γ
(R&D Systems). An additional experiment consisted of the addition of 10ng/ml
recombinant human TNF-α/TNFSF1A in combination with 10-6 molar β-estrogen. IL-2
was reconstituted in 4mM HCl + 1% BSA while TNF-α and IFN-γ were reconstituted
in .01M PBS (pH 7.4) + 1% BSA according to the accompanying protocol (R&D
Systems). β-estrogen was diluted in 100% ethanol and growth media. Because it is
known that IL-2 does not interact with endothelial cells, the addition of IL-2 to the
HUVECs was used as a protein control to demonstrate the protein specificity of any
response to IFN-γ and TNF-α. To account for any cellular response due to HCl, BSA,
PBS buffer or absolute ethanol on the growth conditions, additional control cells were
challenged with 4mM HCl + 1% BSA, .01M PBS + 1% BSA, or PBS plus ethanol.
Cells were harvested at 1 hr, 6hr, 24 hr, and 48hr time points and total RNA was
collected and purified using the protocol in Table 6. After RNA purification and
quantification, the samples were subjected to a reverse-transcriptase enzyme reaction to
prepare cDNA using the Taqman® Reverse Transcription Reagents Kit (ABI) following
the manufacturer’s protocol. As shown in Table 7, the reaction consisted of a master mix
containing reverse Transcriptase Buffer (ABI), MgCl2, dNTPs, Random Hexamers (ABI),
Rnase I, and reverse transcriptase enzyme. To this mix, 400ng/ul RNA sample was
added.
Once cDNA was prepared, the samples were subjected to Real-Time PCR for the
detection of genetic expression of Fgl2 and the housekeeping gene GAPDH using the
Assays-on-DemandTM Gene Expression Products (TaqMan® MGB probes, FAMTM dye-
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labeled) by Applied Biosystems. The set-up for the reactions is shown in table 8A and
8B and each reaction master mix contained Taqman Master Mix (ABI), 20x primer/probe
mix, and deionized water. The reaction was run on the Mx3000P Real-Time PCR
System (Stratagene). Fgl2 and GAPDH assays were ran on the same plate to control for
amplification differences between samples. Control human RNA (Applied Biosystems)
was run alongside the experimental samples as a positive control to ensure the success of
the Fgl2 RT-PCR assay.
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DATA ANALYSIS
The sequence data obtained from the ABI 3100 Genetic Analyzer was entered
into the software program SeqMan II version 5.06 by DNAStar. Here, the sequence
contigs were assembled (based on overlapping sequences) to obtain one single consensus
sequence that was compared against the published sequence for human Fgl2 (accession
number AF468959). Frequencies of the variations between samples among cases and
controls were analyzed for significance through computation of a Chi-square. The Chisquare was performed by the software program SigmaStat by Jandel Scientific.
Results from the RT-PCR Fgl2 gene expression study were analyzed by the
Mx3000P Real-Time PCR System. The software performed a comparative quantitation
based on the generation of a standard curve for relative amounts of template present.
GAPDH was used as a normalizer to correct for differences in total cDNA input between
samples. The Mx3000P software automatically adjusted the levels of Fgl2 for
differences in the levels of GAPDH when generating the standard curve. The
amplification efficiency was then calculated based on the slope of the standard curve
obtained.

QUALITY CONTROL
Sequencing
Pre-PCR work was conducted within UV workstations in a lab separate from the
lab used for post-PCR work (thermocycling, clean-up reactions, and sequencing PCR setup) to avoid possible routes of contamination. Two separate clean-up reactions were
used to remove inhibitors that may interfere with the accurate sequencing of the DNA.
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Automated sequencing was performed in the forward and reverse directions and
variations in individual samples from the published sequence were repeated to correct for
any PCR artifacts or mistakes.

Cell Culture/Gene Expression Assay
Each experiment was set-up alongside three control groups for each time point
collected. The first control consisted of growth media only (no addition of cytokines or
buffers). The second control included the addition of the buffer (PBS or HCl) or PBS
buffer with ethanol that was used to reconstitute the cytokine or estrogen used in the
experiment. The third control was a protein control (IL-2) for the demonstration of a
cellular response due to the specificity of IFN-γ and/or TNF-α. During the RNA→cDNA
reverse transcriptase reaction, as well as the Real Time-PCR reaction, non-template
controls as well as manufactured human RNA controls were run alongside the
experimental samples to diagnose any contamination and evaluate the overall
amplification of the reactions. The Real Time-PCR primers were designed to span exons
and eliminate amplification of any genomic DNA contamination. The amplification
results of Fgl2 were normalized to the housekeeping gene GAPDH to account for any
differences due to varying starting concentrations of cDNA. HUVEC cells from three
different donors were independently cultured and tested for Fgl2 expression. To ensure
the success of the Fgl2 RT-PCR expression assay, positive control human RNA was run
alongside the experimental samples. The RT-PCR reaction was also performed a
minimum of two times on separate days for each donor for a total of seven independent
RT-PCR reactions to ensure reproducibility and consistency in the expression of Fgl2.
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Statistical Analysis
A Chi-square statistical analysis was performed on all sequencing data obtained.
The calculations were made using the program SigmaStat v1.01. A p-value was
calculated to examine whether or not trends in the data were statistically significant. An
accurate Chi-square requires all values to be greater than 1 and no more than 20% of
values less than 5. A p-value of less than .1 was used as a cut-off to determine statistical
significance.

RESULTS
Sequencing
Twelve SNPs were identified at the positions located in the gene map in Figure 1.
A T to A change was seen in nucleotide -1285, a T to C change at nucleotide -759, a T to
A change at -656, an A to G change at -563, a T to C change at -194, a T to C change at
+110, a G to A at +157, a T to C at +2124, a G to T at +2672, a C to T at +3627, a C to T
at +3868, and a T to G at +4619. These variations were observed in a direct submission
of the Fgl2 genetic sequence to NCBI (AF468959), however there have been no analyses
or identification of the SNPs in relation to the +1 translation start site published. This
study defines polymorphisms found in relation to the +1 translation start site, lists their
position and frequencies (Table 9) and analyzes the variations for an association with
women who have suffered from recurrent fetal losses. As seen in Table 9, the frequency
of substitutions at nucleotides -1285 and +110 show a statistically significant difference
between cases and controls (p=.01 and p=.03 respectively). A trend in the difference
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between cases and controls is seen in nucleotides -656, -194, +157, +2124, +2672, and
+3868 but due to small sample size, an accurate Chi square analysis could not be
performed. No statistical difference was seen in cases and controls for nucleotides -759, 563, +3627, and +4619. A novel variation from the published sequence not previously
reported to date is a nucleotide deletion between positions +4612-4619. The reported
sequence contains a string of 8 T’s while the current study found only 7 T’s occurring in
every sample sequenced (170 samples). The raw data and allelic frequencies for the
occurrence of the variations seen in this study are displayed in Table 10. As listed in the
Table, the data is broken into race categories (Caucasian and African American) for cases
and controls. All races (Caucasian, African American, Asian, and Hispanic) were
included in the total results column for cases and controls. An accurate Chi-square
requires all values to be greater than 1 and no more than 20% of values less than 5. Only
one of the SNPs, nt. -1285, met this criteria and was determined to be significantly
related to recurrent fetal loss (p=.01). The variation at nucleotide position +110 was also
calculated to be significant (p=.03), however the power of the test (.6224) was below the
desired power of .800, and therefore should be interpreted cautiously. Due to small
sample size or frequency of the variant allele, the analysis of the remaining variations by
calculation of a p-value from a Chi- square was not accurately determined.
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Gene Expression
Constitutive expression of Fgl2:

When grown in EGM-MV growth media,

expression of Fgl2 by HUVECs was not shown at 1, 6, 24, 48, or 72 hours. Figures 2 and 3 show
the lack of amplification of these samples, as indicated by the lack of change in fluorescent
intensity during the reaction. The human control RNA used as positive controls for the reaction
did amplify, indicating expression of Fgl2 by the samples (plots not shown).
IL-2: As expected, the addition of 10.0ng/ml of IL-2 to the growth media did not induce
the expression of Fgl2 in HUVEC cells from male or female donors. As shown in Figures 4-7,
no change in fluorescence was seen, indicating lack of amplification of the samples. Again, the
human RNA positive controls amplified, indicating the success of the RT-PCR (plots not shown).
IFN-γ: The analysis of total RNA collected from the cells grown in the presence of
10.0ng/ml IFN-γ showed an increase in the expression of Fgl2 in a female donor at the 24 hour
time point. This expression decreases back to zero at 48 hours. The relative change in
fluorescence for these samples can be seen in the linear plot of amplification in Figure 8 and the
graph in Figure 9, where an increase in the relative fluorescence indicates amplification
(expression) of Fgl2. The expression of Fgl2 grown with IFN-γ in HUVEC cells of a male
donor shows an increase of expression at 6 and 24 hours with a decrease of expression at 48
hours , again shown by changes in the relative fluorescent intensity as indicated in Figures 10-11.
Positive control RNA was also amplified (plots not shown).
TNF-α: HUVEC cells from a male donor grown in the presence of 10.0ng/ml TNF-α
showed an increased expression of Fgl2 at 24 hours. This expression decreased at 48 hr.
Figures 14-15 note the change in relative fluorescent intensity for samples influenced by TNF-α.
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The HUVEC cells of a female donor did not show expression of Fgl2 in any of the time points
sampled as shown by the lack of fluorescence seen in Figures12-13.
The gender difference seen in the ability of TNF-α to induce Fgl2 expression in the
HUVEC cells was surprising and led to the investigation of the effect of estrogen on this
induction of Fgl2 expression by TNF-α. As shown in Figure 23, TNF-α was able to induce the
expression of Fgl2 at the 72 hour time-point in HUVECs from a male donor. When estrogen
was added to these cells along with TNF-α, the effect was greatly reduced. This is demonstrated
by the decrease of fluorescence in the relative quantity chart shown in Figure 23.
Each reaction plate showed an increase in relative fluorescence by the positive control
RNA validating the Fgl2 expression assay (plots not shown). In all cell samples (controls, IL-2,
IFN-γ, and TNF-α) presence of RNA/cDNA was shown by the expression of GAPDH at all time
points collected (Figures 16-22 and 24). Variation in the amplification seen in the GAPDH
reactions (some samples were amplified at an earlier cycle than others) can be explained by
differences in starting RNA concentrations for the reaction. RNA concentrations were quantified
by spectrophotometry, however, limitations in pipetting and the spectrophotometer used may
have caused slight variations in concentrations when diluting the RNA for use in the cDNA and
subsequent RT-PCR reactions. Using GAPDH as a control gene to assess the expression of RTPCR assays has recently been under debate due to the variability of its expression levels between
the cells of different tissues and while under different experimental conditions12,13,14. For this
study, however, all RNA samples were prepared from endothelial cells. Additionally, a precise
quantification of cDNA expression for Fgl2 was not needed, as the goal of the project was
simply to differentiate between a yes/no result based on the presence or absence of a change in
the relative fluorescent intensities obtained for Fgl2 expression.
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Well:

FGL2 Expression

A5-Medium 1 hr
B5-Medium 6 hr
C5-Medium 24 hr
D5-Medium 48 hr
E5-Medium 72 hr
F5-PBS 1 hr
G5-PBS 6 hr

Fluorescence

H5-PBS 24 hr
A6-PBS 48 hr
B6-PBS 72 hr
C6-HCl 1hr
D6-HCl 6 hr
E6-HCl 24 hr
F6-HCl 48 hr
G6-HCl 72hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 2 FGL2 Expression in HUVEC Controls: Real-Time PCR Amplification Plot

Relative Quantity Chart: FGL2 Expression

48 hr

72 hr

24 hr

1 hr

6 hr

48 hr

PBS

72 hr

24 hr

6 hr

1 hr

72 hr

24 hr

48 hr
48 hr

6 hr

1 hr

Medium

HCl

Figure 3 FGL2 Expression in HUVEC Controls: Relative Quantity Chart
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HUVECS + IL-2

Female/NB/Caucasian
HUVEC cells
Well:
A9-Medium 1 hr
B9-Medium 6 hr
C9-Medium 24 hr
D9-Medium 48 hr
E9-Medium 72 hr
F9-Control HCl 1 hr
G9-Control HCl 6 hr
H9-Control HCl 24 hr
A10-Control HCl 48 hr
B10-Control HCl 72 hr
H10-IL-2, 1 hr
A11-IL-2, 6 hr
B11-IL-2, 24 hr
C11-IL-2, 48 hr
D11-IL-2, 72 hr

RT-PCR Amplification Plot
(56 Cycles)

Figure 4 Effects of IL-2 on FGL2 Expression in HUVEC cells, Female donor

Relative Quantity Chart: FGL2 expression
Addition of IL-2 to HUVECS (Female)

72 hr

48 hr

24 hr

6 hr

1 hr

72 hr

48 hr

24 hr

6 hr

1 hr

HCl (Buffer Control)

IL-2

Figure 5 Effects of IL-2 on FGL2 Expression in HUVEC cells, Female Donor
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HUVECS + IL-2

Male/NB/Caucasian
HUVEC Cells
Well:

A1- Medium 1 hr
B1- Medium 6 hr
C1- Medium 24 hr
D1- Medium 48 hr
E1- HCl 1 hr
F1- HCl 6 hr
G1- HCl 24 hr
H1- HCl 48 hr
E2- IL-2 1 hr
F2- IL-2 6 hr
G2- IL-2 24 hr
H2- IL-2 48 hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 6 Effects of IL-2 on FGL2 Expression in HUVEC cells, Male Donor

Relative Quantity Chart: FGL2 expression
Addition of IL-2 to HUVECS (Male)

IL-2

48 hr

24 hr

6 hr

1 hr

48 hr

24 hr

6 hr

1 hr

HCl (Buffer Control)

Figure 7 Effects of IL-2 on FGL2 Expression in HUVEC cells, Male Donor
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HUVECS + IFN-γ
Female/NB/Caucasian
HUVEC Cells
Well:

A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
E5- Medium 72 hr
C6- PBS 1 hr
D6- PBS 6 hr
E6- PBS 24 hr
F6- PBS 48 hr
G6- PBS 72 hr
E7- IFN-γ 1 hr
F7- IFN-γ 6 hr
G7- IFN-γ 24 hr
H7- IFN-γ 48 hr
A8- IFN-γ 72 hr

IFN-γ
24 hr

RT-PCR Amplification Plot
(58 Cycles)

Figure 8 Effect of IFN-γ on FGL2 expression in HUVEC cells, Female Donor

Relative Quantity Chart: FGL2 expression
Addition of IFN-γ to HUVECS (Female)

72 hr

48 hr

24 hr

6 hr

1 hr

72 hr

48 hr

24 hr

6 hr

1 hr

PBS (Buffer Control)

IFN-γ

Figure 9 Effects of IFN-γ on FGL2 Expression in HUVEC cells, Female Donor
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HUVECS + IFN-γ
Male/NB/Caucasian
HUVEC Cells
Well:

IFN-γ
6 hr →

A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
C6- PBS 1 hr
D6- PBS 6 hr
E6- PBS 24 hr
F6- PBS 48 hr
A7- IFN-γ 1 hr
B7- IFN-γ 6 hr
C7- IFN-γ 24 hr
D7- IFN-γ 48 hr

IFN-γ
24 hr

IFN-γ
24 hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 10 Effects of IFN-γ on FGL2 expression in HUVEC cell, Male Donor

Relative Quantity Chart: FGL2 expression
Addition of IFN-γ to HUVECS (Male)

48 hr

24 hr

6 hr

1 hr

48 hr

24 hr

6 hr

1 hr

PBS (Buffer Control)

IFN-γ

Figure 11 Effects of IFN-γ on FGL2 Expression in HUVEC cells, Male Donor
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HUVECs + TNF-α

Female/NB/Caucasian
HUVEC Cells
Well:
A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
E5- Medium 72 hr
F5- PBS 1 hr
G5- PBS 6 hr
H5- PBS 24 hr
A6- PBS 48 hr
B6- PBS 72 hr
B8- TNF-α 1 hr
C8- TNF-α 6 hr
D8- TNF-α 24 hr
E8- TNF-α 48 hr
F8- TNF-α 72 hr

RT-PCR Amplification Plot
(58 Cycles)

Figure 12 Effects of TNF-α on FGL2 Expression in HUVEC cells, Female Donor

Relative Quantity Chart: FGL2 expression
Addition of IFN-γ to HUVECS (Female)

72 hr

48 hr

24 hr

6 hr

1 hr

72 hr

24 hr

48 hr

6 hr

1 hr

PBS (Buffer Control)

TNF-α

Figure 13 Effects of TNF-α on FGL2 Expression in HUVEC cells, Female Donor
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HUVECS + TNF-α

Male/NB/Caucasian
HUVEC Cells
Well:

A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
E5- PBS 1 hr
F5- PBS 6 hr
G5- PBS 24 hr
H5- PBS 48 hr
E7- TNF-α 1 hr
F7- TNF-α 6 hr
G7- TNF-α 24 hr
H7- TNF-α 48 hr

TNF-α
24 hr →

RT-PCR Amplification Plot
(65 Cycles)

Figure 14 Effects of TNF-α on FGL2 Expression in HUVEC cells, Male Donor

Relative Quantity Chart: FGL2 expression
Addition of TNF-α to HUVECS (Male)

48 hr

24 hr

6 hr

1 hr

48 hr

24 hr

6 hr

1 hr

PBS (Control Buffer)

TNF-α

Figure 15 Effects of TNF-α on FGL2 Expression in HUVEC cells, Male Donor
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GAPDH Expression
Well:
A5-Medium 1 hr
B5-Medium 6 hr
C5-Medium 24 hr
D5-Medium 48 hr
E5-Medium 72 hr
F5-PBS 1 hr
G5-PBS 6 hr
H5-PBS 24 hr
A6-PBS 48 hr
B6-PBS 72 hr
C6-HCl 1hr
D6-HCl 6 hr
E6-HCl 24 hr
F6-HCl 48 hr
G6-HCl 72hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 16 GAPDH Expression in Control HUVEC cell samples

Female/NB/Caucasian
HUVEC cells
Well:
A9-Medium 1 hr
B9-Medium 6 hr
C9-Medium 24 hr
D9-Medium 48 hr
E9-Medium 72 hr
F9-Control HCl 1 hr
G9-Control HCl 6 hr
H9-Control HCl 24 hr
A10-Control HCl 48 hr
B10-Control HCl 72 hr
H10-IL-2, 1 hr
A11-IL-2, 6 hr
B11-IL-2, 24 hr
C11-IL-2, 48 hr
D11-IL-2, 72 hr

GAPDH Expression

RT-PCR Amplification Plot
(56 Cycles)

Figure 17 Effects of IL-2 on GAPDH Expression in HUVEC cells, Female Donor
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Female/NB/Caucasian
HUVEC Cells
Well:
A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
E5- Medium 72 hr
C6- PBS 1 hr
D6- PBS 6 hr
E6- PBS 24 hr
F6- PBS 48 hr
G6- PBS 72 hr
E7- IFN-γ 1 hr
F7- IFN-γ 6 hr
G7- IFN-γ 24 hr
H7- IFN-γ 48 hr
A8- IFN-γ 72 hr

GAPDH Expression

RT-PCR Amplification Plot
(58 Cycles)

Figure 18 Effects of IL-2 on GAPDH Expression in HUVEC cells, Male Donor

GAPDH Expression
Male/NB/Caucasian
HUVEC Cells
Well:

A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
C6- PBS 1 hr
D6- PBS 6 hr
E6- PBS 24 hr
F6- PBS 48 hr
A7- IFN-γ 1 hr
B7- IFN-γ 6 hr
C7- IFN-γ 24 hr
D7- IFN-γ 48 hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 19 Effects of IFN-γ on GAPDH Expression in HUVEC cells, Female Donor
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GAPDH Expression
Male/NB/Caucasian
HUVEC Cells
Well:
E1- HCl 1 hr
F1- HCl 6 hr
G1- HCl 24 hr
H1- HCl 48 hr
E2- IL-2 1 hr
F2- IL-2 6 hr
G2- IL-2 24 hr
H2- IL-2 48 hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 20 Effects of IFN-γ on GAPDH Expression in HUVEC cells, Male Donor

GAPDH Expression
Male/NB/Caucasian
HUVEC Cells
Well:
A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
E5- PBS 1 hr
F5- PBS 6 hr
G5- PBS 24 hr
H5- PBS 48 hr
E7- TNF-α 1 hr
F7- TNF-α 6 hr
G7- TNF-α 24 hr
H7- TNF-α 48 hr

RT-PCR Amplification Plot
(65 Cycles)

Figure 21 Effects of TNF-α on GAPDH Expression in HUVEC cells, Female Donor
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GAPDH Expression

Female/NB/Caucasian
HUVEC Cells
Well:
A5- Medium 1 hr
B5- Medium 6 hr
C5- Medium 24 hr
D5- Medium 48 hr
E5- Medium 72 hr
F5- PBS 1 hr
G5- PBS 6 hr
H5- PBS 24 hr
A6- PBS 48 hr
B6- PBS 72 hr
B8- TNF-α 1 hr
C8- TNF-α 6 hr
D8- TNF-α 24 hr
E8- TNF-α 48 hr
F8- TNF-α 72 hr

RT-PCR Amplification Plot
(58 Cycles)

Figure 22 Effects of TNF-α on GAPDH Expression in HUVEC cells, Male Donor

Relative Quantity Chart: FGL2 Expression
Addition of TNF-α and Estragen to HUVECs (Male)

72 hr

TNF-α+Estragen

TNF-α

PBS +EtOH

PBS

TNF-α +Estragen

48 hr

Medium

TNF-α

PBS +EtOH

Medium

PBS

TNF-a +Estragen

PBS +EtOH

TNF-α

PBS

Medium

24 hr

M

Figure 23 Effects of the addition of Estrogen to TNF-α induced expression of FGL2
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Male/NB/Caucasian
HUVEC Cells

GAPDH Expression

Well:

B6- Medium 24 hr
B7- Medium 48 hr
B8- Medium 72 hr
C6- PBS 24 hr
C7- PBS 48 hr
C8- PBS 72 hr
D6- PBS +EtOH 24 hr
D7- PBS +EtOH 48 hr
D8- PBS +EtOH 72 hr
E6- TNF-α 24 hr
E7- TNF-α 48 hr
E8- TNF-α 72 hr
F6- TNF-α +Estragen 24 hr
F7- TNF-α +Estragen 48 hr
F8- TNF-α +Estragen 72 hr

RT-PCR Amplification Plot
(64 Cycles)

Figure 24 Effects of TNF-α and Estrogen on GAPDH Expression

DISCUSSION
The T→A substitution at nucleotide -1285 is located 30 bp downstream of a conservative
MIR (Mammalian Interspersed Repeat) region located in the 5’ UTR. MIRs have been
implicated in the expression of several mammalian genes, providing alternative splice sites,
polyadenylation sites and additional protein-coding information15,16. MIR integration has
recently been hypothesized to play a role in gene control and evolution17. This SNP may or may
not affect gene transcription or gene expression. It may, however, be a marker for identifying
cases of recurrent fetal loss.
Nucleotide +110 is located in exon 1 of the coding region of FGL2 and involves a T→C
substitution. This substitution appears to be a silent mutation, as it changes the reading frame
from GAT to GAC, both coding for aspartic acid. This polymorphism was present in the African
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American samples tested but was not seen in the White population tested. A low number of
African American cases present could account for the apparent significance of the calculated pvalue between cases and control samples tested. Increasing the study size to include more
African American cases may eliminate or reduce the significance of this variation.
The novel variation from the published sequence between nucleotides 4612-4619 (7 T’s
instead of 8 T’s, followed by 8 G’s) was seen in every sample tested. Since no representation of
the published sequence was discovered in 170 samples for this region of the 3’ UTR, a mistake
in the original sequence could be possible, since no mention of a nucleotide deletion was made.
Small sample size did not allow the analysis of six additional polymorphisms identified
(nt T-656A, T-194C, G+157A, T+2124C, G+2672T, and C+3868T). Differences in the
frequency of the variant allele between recurrent fetal loss cases and controls are seen and may
suggest a trend for these SNPs. A larger study may indicate a significance that can not be seen in
the present study, as many of these SNPs are located within the promoter and other coding
regions of the Fgl2 gene. T-656A is located 20 bp upstream of TCF1 Ets, a transcription factor
binding site;18 the T→C variation at position -194 is located within the promoter region, halfway between binding sites for C/EBP and SP118. T+2124C and G+2672T are located in intron 1
of the non-coding region and flank the ends of another conservative MIR region. Nucleotide
+3868 (C→T) is located within the Alu insertion in the 3’UTR of the Fgl2 gene. Alu insertions
have been associated with thrombosis and heart disease when located in the introns of the TPA
(tissue plasminogen activator) and ACE (angiotensin-converting enzyme) genes19,20.
The G→A variation seen at position +157 has recently been suggested as a marker for
severe periodontal disease21. Located within the coding region of exon 1, the polymorphism
causes a GGG→GAG change in the reading frame which is responsible for an amino acid
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change from Gly→Glu (glycine to glutamic acid) which can lead to a significant change in the
tertiary structure of a protein. Recent literature supports the hypothesis that chronic oral infection
like periodontal disease contributes to pregnancy complications such as preeclampsia, preterm
birth, fetal growth restriction, and fetal loss22,23. Variations at positions A210G, T165C,
T1239C, and C3124T have been reported in the literature for the sequence associated with
accession number AF468959, but were not seen in the present study in any sample.
Failure to shift from a Th1 to a Th2-type immune response during early pregnancy is
known to be detrimental to a successful pregnancy. This study has shown the ability of the Th1
cytokines IFN-γ and TNF-α to induce the expression of Fgl2 in HUVECs strengthening the role
of Fgl2 expression in the thrombosis associated with human fetal loss. The lack of an
endothelial cell response to the addition of IL-2 further demonstrates the specificity of the
response to the Th1 cytokines IFN-γ and TNF-α.
A small gender difference was seen in Fgl2 expression induced by IFN-γ, in that Fgl2
was expressed at both 6 and 24 hours in cells from a male donor, and only at 24 hours in cells
from a female donor. The sex difference in the expression of Fgl2 in response to TNF-α was not
anticipated and led to the evaluation of the effect of estrogen on this induced expression. As
demonstrated, the addition of estrogen and TNF-α to the male donor HUVEC cells was able to
greatly reduce the effect seen by TNF-α alone. This supports the large gender difference seen in
the expression of Fgl2 in HUVECs induced by TNF-α.
Clotting of the vascular vessels of the placenta and fetus interferes with adequate blood
supply to the fetus. Thrombosis due to the expression of Fgl2 has been shown to cause fetal loss
in mice and increased expression of Fgl2 in human trophoblast cells in uterine tissue taken from
fetal losses suggests a similar role for Fgl2 in the thrombosis associated with human fetal loss.
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The ability of estrogen to eliminate the response of HUVECs to TNF-α in male cells (mimicking
the female system) suggests an additional role of estrogen in maintaining a healthy pregnancy.
This role could be to protect the pregnancy during times of infection and a Th1-type immune
response from activating the prothrombinase Fgl2 and thus prevent clotting of the placental
vessels. This effect might also be involved in the thrombosis associated with cardiovascular
disease.
A complex balance between vasodilatory and vasoconstrictory factors and mediators
maintains vascular function24,25. The incidence of coronary artery disease and stroke in women
rises after menopause (when the levels of estrogen decrease), pointing at the important vascular
role of estrogen. Coronary artery disease and stroke are the primary causes of death in women
after the age of 60. There is about a 50% chance of a post-menopausal woman to develop heart
disease in her lifetime, while there is a 30% probability she will die from it26. Stroke remains a
leading cause of disability and death of women and recent data suggest that one in six women in
western countries will die of stroke27. The gender difference exhibited by endothelial cells in
response to TNF-α and its ability to induce expression of the procoagulant Fgl2 invites
additional studies into this effect in relation to cardiovascular disease. Future research is
suggested to compare HUVECs as well as macrophages from pre-menopausal female donors to
post-menopausal female donors under conditions favoring the Th1 response (TNF-α) and the
induction of Fgl2 gene expression.

44
REFERENCES
1. Koyama T, Hall LR, Haser WG, Tonegawa S, Saito H. Structure of a cytotoxic Tlymphocyte-specific gene shows a strong homology to fibrinogen beta and gamma
chains. Proceedings of the National Academy of Science USA. 1987; 84: 10691613.
2. Pope M, Rotstein O, Cole E, Sinclair S, Parr R, Cruz B, Fingerote R, Chung S,
Gorczynski R, Fung L, Leibowitz J, Rao YS, Levy G. Pattern of disease after
murine
hepatitis virus strain 3 infection correlates with macrophage activation and not viral
replication. Journal of Virology. 1995; 69: 5252-5260.
3. Parr RL, Fung LS, Reneker J, Myers-Mason N, Leibowitz JL and Levy GA.
Association of mouse fibrinogen like protein with murine hepatitis virus induced
prothrombinase activity. Journal of Virology. 1995; 69: 5033-5038.
4. Ning Q, Liu M, Kongkham P, Lai M, Marsden P, Tseng J, Pereira B, Belyavskyi M,
Leibowtiz J, Phillips JM, and Levy GA. The nucleocapsid protein of murine hepatitis
virus type 3 induces transcription of the novel fgl2 prothrombinase gene. Journal
Biological Chemistry. 1999; 274: 9930-9936.
5. Ding JW, Ning Q, Liu MF, Lai A, Leibowitz J, Peltekian KM, Cole EH, Fung LS,
Holloway C, Marsden PA, Yeger H, Phillips MJ, Levy GA. Fulminant hepatic
failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a
novel fgl2 prothrombinase. Journal of Virology. 1997; 71: 9223-9230.
6. Clark, D, Ding J, Chaouat G, Coulam C, August C, Levy, GA. The emerging Role of
Immunoregulation of Fibrinogen-Related Procoagulant Fgl2 in the Success or
Spontaneous Abortion of Early Pregnancy in Mice and Humans. American
Journal of Reproductive Immunology. 1999; 42: 37- 43.
7. Hancock W, Szaba F, Berggren K, Parent M, Mullarky I, Pearl J, Cooper A, Ely K,
Woodland D, Kim I, Blackman M, Johnson L, Smiley S. Intact type 1 immunity and
immune-associated coagulative responses in mice lacking IFN-γ-inducible
fibrinogen-like protein 2. Proceedings of the National Academy of Science. 2004;
101: 3005-3010.
8. Ghanekar A, Mendicino M, Liu H, He W, Liu M, Zhong R, Phillips MJ, Levy GA,
Grant D. Endothelial Induction of fgl2 contributes to Thrombosis during Acute
Vascular Xenograft Rejection. Journal of Immunology. 2004; 172: 5693-5701.
9. Ruegg C, Pytela R. Sequence of a human transcript expressed in T-lymphocytes
and encoding a fibrinogen-like protein. Gene. 1995; 160: 257-262.

45

10. Marazzi S, Blum S, Hartmann, R, Gundersen, D, Schreyer M, Argraves S, Fliedner
V, Pytela R, and Ruegg C. Characterization of human fibroleukin, a fibrinogen
like protein secreted by T lymphocytes. Journal of Immunology. 1998; 161: 138147.
11. SeattleSNPs. NGLBI Program for Genomic Applications, UW-FHCRC, Seattle,
WA (URL: http://pga.mbt.washington.edu ). Homo sapiens fibrinogen-like 2
(FGL2) gene, complete cds. Direct Submission to NCBI, Accession number
AF468959
12. Dheda K, Hugget J, Bustin S, Johnson M, Rook G, and Zumla A. Validation of
housekeeping genes for normalizing RNA expression in real-time PCR.
BioTechniques. 2004; 37: 112-119.
13. Aerts J, Gonzales M, and Topalian S. Selection of appropriate control genes to
assess expression of tumor antigens using real-time RT-PCR. BioTechniques.
2004; 36: 84-91.
14. Bustin SA. Absolute quantification of mRNA using real-time reverse
transcription polymerase chain reaction assays. Journal of Molecular
Endocrinology. 2000; 25: 169-193.
15. Murnane, JP and Morales JF. Use of a mammalian interspersed repetitive (MIR)
element in the coding and processing sequences of mammalian genes. Nucleic
Acids Research. 1995; 23: 2837-2839.
16. Tulko, JS et al. MIRs are present in the coding regions of human genes. DNA
Sequencing. 1997; 8: 31-38.
17. Hughs, David C. MIRs as agents of mammalian gene evolution. Trends in
Genetics. 2000; 16: 60-62
18. Yuwaraj S, Ding J, Liu M, Marsden P, Levy GA. Genomic Characterization,
Localization, and Functional Expression of FGL2, the Human Gene Encoding
Fibroleukin: A Novel Human Procoagulant. Genomics. 2001; 71: 330-338.
19. Ridker P, Baker M, Hennekens C, Stampfer M, Vaughan D. Alu-repeat
Polymorphism in the Gene Coding for Tissue-Type Plasminogen Activator (tPA) and Risks of Myocardial Infarction Among Middle-aged Men.
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; 17: 1687-1690.
20. Baudin B. New aspects on angiotensin-converting enzyme: from gene to
disease. Clinical Chemistry and Laboratory Medicine. 2002; 40: 256-265.

46
21. Suzuki A, Guijin J, Yukihiro N, Keisuke I, Masaaki M, Kyuichi K. Large-scale
investigation of genomic markers for severe periodontitis. Odontology. 2004; 92: 43-47.
22. Boggess K, Lieff S, Murtha A. Maternal periodontal disease is associated
with an increased risk for preeclampsia. Obstetrics and Gynecology. 2003; 101: 227-231.
23. Offenbacher S, Lieff S, Boggess K. Maternal periodontitis and prematurity.
Part I: Obstetric outcome of prematurity and growth restriction. Annals of
Periodontology. 2001; 6: 164-174.
24. Mendelsohn M, Karas R. Mechanisms of disease: the protective effects of
estrogen on the cardiovascular system. New England Journal of Medicine. 1999;
340: 1801-1811.
25. Austin C. Chronic and acute effects of oestrogens on vascular contractility.
Journal of Hypertension. 2000; 18: 1365-1378.
26. Grady D, Rubin S, Petiti D. Hormone therapy to prevent disease and prolong life
in postmenopausal women. Annals of Internal Medicine. 1992; 117: 1016-1037.
27. Bonita R. Epidemiology of stroke. Lancet. 1992; 339: 342-344.

